Literature DB >> 7770126

Follow-up of optic pathway gliomas in children with neurofibromatosis type 1.

C Kuenzle1, M Weissert, E Roulet, H Bode, S Schefer, T Huisman, K Landau, E Boltshauser.   

Abstract

Optic pathway gliomas (OPG) are found in about 15% of patients with neurofibromatosis Type 1 (NF-1). The natural history of OPG is not yet well documented. Treatment in cases with growing tumors is still controversial. Twenty-one patients with NF-1 and OPG, diagnosed over a 20-year period, and followed neuroradiologically and ophthalmologically for at least two years, were reevaluated. The diagnosis of OPG was made at a mean age of 7.1 years (range 0-14.5 years); six children were asymptomatic, 15 were symptomatic. The mean follow-up was 9.0 years (2.0-18.5 (years). In eight initially operated or biopsied patients (three optic nerve and five chiasmal gliomas) tumor regrowth was found in one patient without progression on subsequent follow-up. Improvement of visual acuity occurred in one child after operation of a large suprasellar tumor and deterioration in one patient after biopsy of a chiasmal glioma. The neuroradiological follow-up of the 13 not-operated and not-radiated patients (four optic nerve and nine chiasmal gliomas) was stable in 10, progressive in three, resulting in visual loss in one patient. In 11 children (52%) a second tumor outside the optic pathway was found at a mean age of 4.0 years after the diagnosis of an OPG. Until now they are mostly asymptomatic. Second site tumors were operated in two children because of rapid tumor growth, one child died of a brainstem tumor. OPG are a frequent complication in children with NF-1, appearing within the first decade.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 7770126     DOI: 10.1055/s-2008-1073043

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  8 in total

1.  Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis.

Authors:  L Kornreich; S Blaser; M Schwarz; A Shuper; T H Vishne; I J Cohen; R Faingold; S Michovitz; B Koplewitz; G Horev
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

2.  Visual pathway glioma: an erratic tumour with therapeutic dilemmas.

Authors:  A Shuper; G Horev; L Kornreich; S Michowiz; R Weitz; R Zaizov; I J Cohen
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

3.  Rare Presentation of Neurofibromatosis and Turner Syndrome in a Pediatric Patient.

Authors:  Natalie Gengel; Ian Marshall
Journal:  Pediatr Rep       Date:  2017-06-27

4.  Investigation of retinal nerve fiber layer thickness in patients with neurofibromatosis-1.

Authors:  Pinar Topcu-Yilmaz; Burcu Kasim; Hayyam Kiratli
Journal:  Jpn J Ophthalmol       Date:  2014-02-04       Impact factor: 2.447

5.  Central and peripheral steady-state visual evoked potentials in children with optic pathway gliomas.

Authors:  Sarah Zakaib Rassi; Luis H Ospina; Ariane Bochereau; Yvan Samson; Sébastien Perreault; Dave Saint-Amour
Journal:  Doc Ophthalmol       Date:  2019-06-26       Impact factor: 2.379

6.  Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1.

Authors:  Patrícia de Freitas Dotto; Adriana Berezovsky; Andrea Maria Cappellano; Nasjla Saba da Silva; Paula Yuri Sacai; Frederico Adolfo B Silva; Arthur Gustavo Fernandes; Daniel Martins Rocha; Solange Rios Salomão
Journal:  Doc Ophthalmol       Date:  2018-05-15       Impact factor: 2.379

7.  Visual evoked potentials in children with neurofibromatosis type 1.

Authors:  Alessandro Iannaccone; Richard A McCluney; Vickie R Brewer; Peter H Spiegel; June S Taylor; Natalie C Kerr; Enikö K Pivnick
Journal:  Doc Ophthalmol       Date:  2002-07       Impact factor: 2.379

Review 8.  Pediatric low-grade glioma in the era of molecular diagnostics.

Authors:  Scott Ryall; Uri Tabori; Cynthia Hawkins
Journal:  Acta Neuropathol Commun       Date:  2020-03-12       Impact factor: 7.801

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.